We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence.
- Authors
Hu, Rachel; George, Daniel J.; Zhang, Tian
- Abstract
Prostate cancer is the most common cancer in men and the second most deadly. About one-third of patients with prostate cancer will develop metastatic disease. We discuss the six United States Food and Drug Administration (FDA) approved treatments for metastatic castrate-resistant prostate cancer (mCRPC) with a strong focus on sipuleucel-T. Sipuleucel-T is the first immunotherapy shown to improve survival in asymptomatic or minimally-symptomatic mCRPC. Herein, we discuss the proposed mechanism of sipuleucel-T and its synthesis. We describe in detail the three randomized controlled trials (RTCs) that led to its approval. We also compiled the newest research regarding use of sipuleucel-T with other agents and in different patient populations. Finally, we discuss the current ongoing trials.
- Publication
Therapeutic Advances in Urology, 2016, Vol 8, Issue 4, p272
- ISSN
1756-2872
- Publication type
Article
- DOI
10.1177/1756287216645314